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Aim of Study: The 2005 release of the Cochrane Review on glu- 
cosamine use in osteoarthritis outlined a moderate to large ef- 
fect size on osteoarthritis symptoms in trials using the original 
crystalline glucosamine sulfate prescription preparation. Never- 
theless, a small effect size was pointed out on WOMAC pain and 
function scores. Since the WOMAC index was used only in the 
two long-term 3-year trials with this formulation, we wanted to in- 
vestigate whether the mild severity characteristics of the patients 
enrolled in such particular trials affected this effect size, and if 
the difference observed with placebo was in any case clinically 
relevant, besides being statistically significant. 
Methods: Patients completing the 3-year treatment course in the 
randomised, double-blind, placebo-controlled trials of Reginster 
2001 and Pavelka 2002, were pooled in a single database. The 
Minimal Clinically Important Improvement (MCII) and Patient Ac- 
ceptable Symptom State (PASS) for WOMAC pain and function 
scores, were calculated according to Tubach 2005. The propor- 
tion of patients achieving such thresholds were compared be- 
tween groups by the chi-square test. 
Results: Out of the 259 completers (126 with placebo and 133 
with glucosamine sulfate), over 50% were in PASS at the end of 
the studies regardless of treatment. However, they were 68.4% 
for WOMAC pain with glucosamine sulfate vs. 55.6% with placebo 
(p=0.033), and 63.9% vs. 50.0% on WOMAC function (p=0.024). 
Patients reporting MCII on WOMAC pain were 39.8% vs. 27.8%, 
respectively (p=0.040). 
Conclusions: The mild severity characteristics of the patients 
enrolled in the two long-term trials with glucosamine sulfate al- 
lowed the vast majority of them to be in an acceptable symptom 
state, thus preventing the possibility of observing the moderate 
to large effect size for improvement hat was reported in shorter 
studies. Nevertheless, there was a clinically relevant and signifi- 
cant difference of 10-15% in favor of glucosamine sulfate in the 
proportion of patients reaching MCII and PASS on pain and func- 
tion. 
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Aim: The PASS is an absolute threshold value proposed for 
symptomatic variables in osteoarthritis (OA) to determine the 
point beyond which patients consider themselves well. The PASS 
differs from the baseline-dependent minimal clinically important 
difference. If the patient meets the PASS threshold, they achieve 
an acceptable symptom state regardless of their change from 
baseline in visual analogue scale (VAS) score. This makes the 
PASS a clinically relevant treatment target. In knee OA, PASS 
thresholds (on a 0-100 VAS scale) have been recently proposed 
as 32.3 mm for pain, 32.0 mm for patient's global assessment of 
disease activity and 31.0 mm for the WOMAC TM function subscale 
score. In previous analyses, lumiracoxib 100 mg once daily (od) 
was found to be significantly superior to placebo and non-inferior 
to celecoxib 200 mg od after 13 weeks in knee OA with respect to 
standard OA outcome variables. To assess the clinical relevance 
of these results from the perspective of the patient, the same data 
pooled from two large studies of knee OA were analyzed with re- 
spect to the PASS criteria for knee OA. 
Methods: A total of 3235 patients were included in two multicen- 
ter, randomized, double-blind studies of identical design. Patients 
with an OA pain intensity in the target knee _>40 mm on a 100 
mm VAS were included; no flare was required. After a 3-7-day 
washout of previous NSAID/analgesic therapy, patients were ran- 
domized to receive lumiracoxib 100 mg od (n=811), lumiracoxib 
100 mg od with a loading dose of lumiracoxib 200 mg od for the 
first two weeks (n=805), celecoxib 200 mg od (n=813) or placebo 
(n=806) for 13 weeks. The average effect of the two lumiracoxib 
100 mg od regimens at 13 weeks was contrasted with the ef- 
fects of celecoxib and placebo. Treatments were compared with 
respect to the PASS criteria (for OA pain, patient's global assess- 
ment of disease activity, and the WOMAC TM function [difficulty in 
performing daily activities] sub-scale score). 
Results: Significant proportions of patients on lumiracoxib 
achieved a PASS (all three definitions) and lumiracoxib was sig- 
nificantly superior to placebo (all p<0.05). 
Conclusion: PASS is an important concept in determining the 
clinical relevance of OA treatments. Percentages of patients on 
lumiracoxib 100 mg od who achieved a PASS were similar to 
those on celecoxib 200 mg od and significantly superior to those 
on placebo. This post-hoc analysis using PASS criteria suggests 
that the efficacy of lumiracoxib 100 mg od is of clinical relevance 
from the patient's perspective. 
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COMPARE THE EFFICACY OF LATERAL WEDGED 
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DEFORMITY OSTEOARTHRIT IS  OF THE KNEE 
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Aim of Study: In our previous study, we demonstrated that in- 
soles with subtalar strapping (the strapped insole) maintained 
the valgus correction of the femorotibial angle (FTA) in patients 
with osteoarthritis varus deformity of the knee (knee OA) for six 
months. However, the six-month observation period was too short 
to evaluate the effect of the strapped insole on the progression of 
varus deformity of knee OA. Therefore, we continued to assess 
Abstract P130 - Table 1. Percentage of patients achieving the PASS threshold criteria 
PASS threshold criteria Lumiracoxib 100 mg od (n=1616) Celecoxib 200 mg od (n=813) 
OA pain intensity (100 mm VAS) 832.3 44.3* 42.2* 
Patient global assessment of disease activity (100 mm VAS) 832.0 43.3* 39.5* 
WOMACTM function sub-scale score (100 mm VAS) 831.0 41.5* 38.6* 
* p<0.05 vs placebo. 
Placebo (n=806) 
35.4 
32.7 
29.4 
